| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Tumor Biology |
Lineberger Comprehensive Cancer Center [W. G. Y., M. B., A. Z., Y. X.], Departments of Otolaryngology/Head and Neck Surgery [W. G. Y., A. Z.] and Biochemistry and Biophysics [W. G. Y., Y. X.], and Program in Molecular Biology and Biotechnology [W. G. Y., Y. X.], School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, 27599-3280, and Department of Functional Genetics, GlaxoSmithKline Pharmaceuticals, Research Triangle Park, North Carolina 27709 [J. E. B.]
Using alternative reading frames, the human ARF-INK4a locus encodes two unrelated proteins that both function in tumor suppression. p16INK4a maintains the retinoblastoma protein in its growth-suppressive state through inhibition of cyclin D-dependent kinase activity, whereas ARF binds with MDM2 and stabilizes p53. The majority of the activity of ARF to date is ascribed to its ability to activate p53, resulting in a G1 cell cycle arrest or apoptosis. We show here that ARF colocalizes with DNA replication protein A (RPA32) and that overexpression of ARF reduces the rate of DNA synthesis resulting in accumulation of an S-phase cell population. Impediment of DNA synthesis by ARF can occur and becomes more evident in the absence of p53. Hence, the biological consequence of ARF induction varies dependent on cellular p53 status, inducing predominantly a G1 arrest or apoptosis in p53-positive cells or causing S-phase retardation when p53 function is comprised.
This article has been cited by other articles:
![]() |
V. S. Tompkins, J. Hagen, A. A. Frazier, T. Lushnikova, M. P. Fitzgerald, A. di Tommaso, V. Ladeveze, F. E. Domann, C. M. Eischen, and D. E. Quelle A Novel Nuclear Interactor of ARF and MDM2 (NIAM) That Maintains Chromosomal Stability J. Biol. Chem., January 12, 2007; 282(2): 1322 - 1333. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Paliwal, S. Pande, R. C. Kovi, N. E. Sharpless, N. Bardeesy, and S. R. Grossman Targeting of C-Terminal Binding Protein (CtBP) by ARF Results in p53-Independent Apoptosis. Mol. Cell. Biol., March 1, 2006; 26(6): 2360 - 2372. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Kwong, L. H. Kalish, T. V. Nguyen, J. G. Kench, R. J. Bova, I. E. Cole, E. A. Musgrove, and R. L. Sutherland p14ARF Protein Expression Is a Predictor of Both Relapse and Survival in Squamous Cell Carcinoma of the Anterior Tongue Clin. Cancer Res., June 1, 2005; 11(11): 4107 - 4116. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Grafstrom, S. Egyhazi, U. Ringborg, J. Hansson, and A. Platz Biallelic Deletions in INK4 in Cutaneous Melanoma Are Common and Associated with Decreased Survival Clin. Cancer Res., April 15, 2005; 11(8): 2991 - 2997. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Normand, P. G. Hemmati, B. Verdoodt, C. von Haefen, J. Wendt, D. Guner, E. May, B. Dorken, and P. T. Daniel p14ARF Induces G2 Cell Cycle Arrest in p53- and p21-deficient Cells by Down-regulating p34cdc2 Kinase Activity J. Biol. Chem., February 25, 2005; 280(8): 7118 - 7130. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. L. Woods, D. P. Xirodimas, A. R. Prescott, A. Sparks, D. P. Lane, and M. K. Saville p14 Arf Promotes Small Ubiquitin-like Modifier Conjugation of Werners Helicase J. Biol. Chem., November 26, 2004; 279(48): 50157 - 50166. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Yi, A. Shepard, F. Kittrell, B. Mulac-Jericevic, D. Medina, and T. K. Said p19ARF Determines the Balance between Normal Cell Proliferation Rate and Apoptosis during Mammary Gland Development Mol. Biol. Cell, May 1, 2004; 15(5): 2302 - 2311. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Sachs, N. E. Sharpless, R. A. DePinho, and N. Rosenberg p16Ink4a Interferes with Abelson Virus Transformation by Enhancing Apoptosis J. Virol., April 1, 2004; 78(7): 3304 - 3311. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Pedersen, S. Mortensen, S. B. Sorensen, M. W. Pedersen, K. Rieneck, L. F. Bovin, and H. S. Poulsen Transcriptional Gene Expression Profiling of Small Cell Lung Cancer Cells Cancer Res., April 15, 2003; 63(8): 1943 - 1953. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Rizos, E. Diefenbach, P. Badhwar, S. Woodruff, T. M. Becker, R. J. Rooney, and R. F. Kefford Association of p14ARF with the p120E4F Transcriptional Repressor Enhances Cell Cycle Inhibition J. Biol. Chem., February 7, 2003; 278(7): 4981 - 4989. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Y. Tsai, D. MacPherson, D. A. Rubinson, A. Yu. Nikitin, R. Bronson, K. L. Mercer, D. Crowley, and T. Jacks ARF mutation accelerates pituitary tumor development in Rb+/- mice PNAS, December 24, 2002; 99(26): 16865 - 16870. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |